

Pediatric Asthma 2011

Wendy L. Wright, MS, APRN, BC, FAANP
Adult/Family Nurse Practitioner
Owner - Wright & Associates Family Healthcare
Amherst, NH
Owner – Anderson Family Healthcare
Concord, NH
Adjunct Faculty - University of Wyoming
Fay W. Whitney School of Nursing
Partner – Partners in Healthcare Education
www.4healtheducation.com

1

Objectives

Upon completion, the participant will be able to:

1. Identify statistics related to incidence/prevalence of asthma
2. Discuss the signs and symptoms of asthma
3. Discuss treatment options for asthma

2

Asthma

3

Asthma is...

- Derived from the Greek word for panting or breathlessness
- Recurrent airflow obstruction caused by chronic airway inflammation with a superimposed bronchospasm
- Leads to... wheezing, breathlessness and a cough

Guidelines for the Diagnosis and Management of Asthma—Update on Selected Topics 2002. NIH, NHLBI. June 2002. NIH publication no. 02-5075.

4

Prevalence of Asthma

- Impacts approximately 21 million individuals in the United States
- Most common chronic disease of childhood affecting 6 million children
- Before adolescence, 2 times more common in boys
- Increasing incidence of this disease
–76% increase in the prevalence of asthma within the past decade

Guidelines for the Diagnosis and Management of Asthma—Update on Selected Topics 2002. NIH, NHLBI. June 2002. NIH publication no. 02-5075.

5


Important Asthma Statistics

- In 2008, an estimated 23.3 million Americans suffered from asthma¹
In comparison, in 2007, approximately:
 - 27 million had heart disease^{2*}
 - 18 million had diabetes³
 - 12 million had cancer^{4††}
- Asthma prevalence was¹
 - 10.6% in African Americans
 - 7.8% in Caucasians
 - 5.8% in Hispanics
- The estimated annual direct healthcare cost of asthma was approximately \$15.6 billion; indirect costs (eg, lost productivity) added another \$5.1 billion, for a total of \$20.7 billion¹
Prescription drugs represented the largest single direct cost, at \$5.6 billion

*Heart disease includes coronary heart disease, angina pectoris, heart attack, or any other heart condition or disease in patients aged 18 and older. †Diagnosed patients in 2007.

†Includes any persons alive before 2007 who had been diagnosed at any sites with active disease and those who were cured.

1. American Lung Association. www.lungusa.org/funding_care/our_research/trend_reports/asthma_trend_report.pdf. Accessed November 30, 2010. 2. Pless JR et al. Vital Health Stat. 10(242). 2009. www.cdc.gov/nchs/data/series/sr_10/sr10_242.pdf. Accessed November 30, 2010. 3. US Centers for Disease Control and Prevention. www.cdc.gov/diabetes/pubsp/ldr1g_2007.pdf. Accessed November 30, 2010. 4. National Cancer Institute. 6 Surveillance Epidemiology and End Results. http://seer.cancer.gov/statfacts/html/nbrbrrvnlw.htm. Accessed November 3, 2010.



Why Is the Death Rate Increasing?

- Multifactorial
 - Asthma is increasing
 - Asthma is more severe
 - Poor management of the disease
 - Poor patient compliance
 - Inadequate patient and provider response to signs of worsening trouble

8

Misconceptions and Facts

- Asthma symptoms can begin at any age
- Most often misdiagnosed or underdiagnosed in the elderly
 - Fail to report symptoms because it is thought to be normal
 - Attribute the symptoms to comorbid diseases

Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma-United States, 1980-1999. MMWR Surveill Summ. 2002;51:1-13. 9

Misconceptions

- Most people think that children will outgrow asthma...
 - Children who suffer from intermittent wheezes have a 50% chance or better of outgrowing this disease
 - Children with persistent wheezing have only a 5% chance of outgrowing this disease

Fuerra S, Wright AL, Morgan WJ, et al. Persistence of asthma symptoms: role of obesity and onset of puberty. Am J Respir Crit Care Med. 2004;170:78-85. 10

Pathophysiology of Asthma

- Genetic predisposition
 - Chromosome: 5Q31-Q33
- Results from repeated exposure to allergens in the individual already equipped with the genetic predisposition
- Upon exposure to an allergen, there is a release of IgE antibodies
- IgE antibody binds with the antigen

11

Pathophysiology of Asthma

- IgE/allergen complex - then attaches itself to the mast cells on the nasal and bronchial mucosa
- Release of numerous chemical mediators


12

Histamine

- Histamine is stored mainly in the mast cell
 - Circulated in the blood via the basophil
- Causes an increase in blood flow to the affected area.
 - Responsible for the increased nasal discharge, edematous mucous membranes, sneezing, itchy nose and eyes, and hives
 - Also associated with airway inflammation and bronchoconstriction


13

Components of Asthma




14

Consequences of Inflammation in Asthma




15

Asthma: Pathophysiologic Features and Changes in Airway Morphology



16


Cross Section of Bronchiole Showing Bronchospasm



Color Atlas of Respiratory Disease. Volume 2, 1995.

17

Epithelial Damage in Asthma




Normal
Jeffery P. In: *Asthma*, Academic Press 1998.

Asthmatic

18

Basement Membrane Thickening



Jeffery P. In: Asthma, Academic Press 1998.

19

Triggers

- Inhalant allergens are the most common triggers for both asthma
 - House dust
 - Pollens
 - Mold spores
 - Animal and insect emanations
 - Cockroach feces

20

Triggers

- Chemicals
- Perfumes
- Foods
 - Sulfites (wine), shrimp, dried fruit, processed potatoes, beer
- Viruses or infections
- Cold air

21

Triggers

- Tobacco smoke
- Pollution
 - Work exposures
- Exercise

22

Gastroesophageal Reflux - A Significant Factor in Children

- 84 healthy infants and children referred for an evaluation of daily wheezing
 - All evaluated for reflux
 - 64% had positive evaluations for reflux
 - After 3 months on anti-reflux treatment, 64.8% of the infants/children were able to discontinue all daily asthma medications (including nebulized flunisolide)

Sheikh S. et. Al. Pediatric Pulmonology. 1999 Sep; 28(3): 181-6

23

Asthma is...

- A disease of:
 - Inflammation
 - Primary Process
 - Hyperresponsiveness
 - Airway bronchoconstriction
 - Excessive mucous production

24

Diagnosis of Asthma

25

- ## Diagnosis of Asthma
- History and Physical Examination
 - Spirometry is needed to make diagnosis
 - Monitoring:
 - Peak Flow Meters
- 26

- ## Symptoms and Signs of Asthma in Children and Adults
- Coughing, particularly at night or after exercise
 - Wheezing
 - Chest tightness
 - SOB
 - Cold that lingers x months
- 27




FIGURE 3-4c. CLASSIFYING ASTHMA SEVERITY IN YOUTHS ≥12 YEARS OF AGE AND ADULTS



Classifying severity for patients who are not currently taking long-term control medications.

| Components of Severity | | Classification of Asthma Severity (Youths ≥12 years of age and adults) | | | |
|-------------------------------|---|--|---|--|--|
| | | Intermittent | Mild | Moderate | Severe |
| Impairment | Symptoms | <2 days/week | >2 days/week but not daily | Daily | Throughout the day |
| | Nighttime awakenings | <2/month | 3-4/month | >1x/week but not nightly | Often 7x/week |
| | Short-acting beta ₂ -agonist use for symptom control (not prevention of FEV ₁) | <2 days/week | >2 days/week but not >1x/day | Daily | Several times per day |
| Normal FEV ₁ /FVC: | Interference with normal activity | None | Minor limitation | Some limitation | Extremely limited |
| | Lung function | • Normal FEV ₁ between exacerbations • FEV ₁ >80% predicted • FEV ₁ /FVC normal | • FEV ₁ <80% predicted • FEV ₁ /FVC normal | • FEV ₁ <60% but >40% predicted • FEV ₁ /FVC reduced 3% | • FEV ₁ <50% predicted • FEV ₁ /FVC reduced >5% |
| Risk | Exacerbations requiring oral corticosteroids | 0-1/year (see note) | 2/year (see note) | >2/year (see note) | >2/year (see note) |

Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs.

At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (e.g., requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had 22 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.

- ## Asthma Findings
- Typically, reversibility of 12% or greater after administration of a bronchodilator aerosol is consistent with asthma.
- Conboy-Ellis, Kathleen. Asthma: Pathogenesis and Management. *The Nurse Practitioner*: November 2006; Vol.31, No. 11. 24 – 39.
- 30



- ### The Biggest Predictor of Sudden Death from Asthma
- History of hospitalization with or without intubation
 - These individuals are at a significant risk for a serious exacerbation again
- 33

Asthma

- Hyperinflation
- Diaphragm is down to the 11th ribs
- Most patients with asthma have normal x-rays

A

34

Chronic Asthma Changes


- Increased AP Lateral diameter
- The way you know that AP/Lat diameter is increased is by this clear space between the sternum and the ascending aorta
- Flat diaphragms

B

35

Treatment of Asthma

36



Environmental Control: A Useful but Often Ignored Step

- **Dust Mite Avoidance**
 - Bed linens must be laundered 1-2 times/week
 - Maintain humidity at <50%
 - Encase pillows and mattresses
 - Frequent vacuuming
 - Remember: 30 minutes after vacuuming: increased dust mite emanations in the air
 - Individuals with significant asthma should avoid vacuuming or avoid the room for 30 minutes after vacuuming

Environmental Control: A Useful but Often Ignored Step

- **Pollen Avoidance**
 - Air-conditioning
 - Minimize outdoor exposures during times of highest pollen counts
 - Keep bedroom windows closed
 - Air filters

Environmental Control

- **Animal Avoidance**
 - Keep animals out of the bedroom
 - If the family has a cat, weekly washing of the cat significantly reduces the allergen load
 - May have to remove animals from home
 - Dry clean upholstery and carpets
 - Cover with an air filter any ducts leading into the bedroom

Environmental Control

- **Mold Avoidance**
 - Children/adolescents with allergic rhinitis and/or asthma should not be sleeping in a damp basement
 - Clean moldy surfaces
 - Avoid houseplants
 - Avoid chores that involve damp grass, leaves

Environmental Control

- **Avoidance of Non-allergic Triggers**
 - Strong emotions
 - Smoke: No smoking in house or car
 - Pollution
 - Cold air
 - Odors
 - Exercise

Childhood Asthma Control Can Predict Adult Lung Status

- Study of 119 asthmatic children during 1966 and 1969
- Ages: 5-14 were evaluated using FEV1
- Follow-up performed 17-18 years later and 27-28 years later
- Children who were well controlled during childhood had the smallest decline in total lung volume during adulthood

43


How Are We Doing With Treatment?

- Study looking at treatment of children over 10 year period showed an increase in the number of prescriptions for beta agonists
 - 4.0% up to 8.1%
- However, despite the significant increase in beta agonist prescriptions, there was only a slight increase in anti-inflammatory medications prescribed (even amongst children using 2+ rescue inhalers/month)
 - 0.4% up to 2.4%

Goodman, DC et al. Pediatrics 1999 Aug; 104(2) 187-94

44

Stepwise Approach for Managing Asthma in Patients Aged ≥12 Years: NAEPP EPR-3 Guidelines



45

45

Step Approach to Therapy

- If control is not achieved with therapy, step up the therapy
- Once control is sustained for a minimum of 3 months, can consider stepping down the therapy
- Regardless, therapy should be reviewed q 6 months

46

Major Focus in EPR-3

- Controlling asthma is a major focus of the EPR-3 guidelines

47

FIGURE 3–5c. ASSESSING ASTHMA CONTROL IN YOUTHS ≥12 YEARS OF AGE AND ADULTS

| Components of Control | | Classification of Asthma Control (Youths ≥12 years of age and adults) | | |
|-----------------------|---|--|---------------------------------|-------------------------------|
| | | Well-Controlled | Not Well-Controlled | Very Poorly Controlled |
| Impairment | Symptoms | <2 days/week | >2 days/week | Throughout the day |
| | Nighttime awakening | <2/month | 1–3x/week | >4x/week |
| | Interference with normal activity | None | Some limitation | Extremely limited |
| | Short-acting beta ₂ -agonist use for symptom control (not prevention of EIB) | <2 days/week | >2 days/week | Several times per day |
| | FEV ₁ or peak flow | >80% predicted/ personal best | 60–80% predicted/ personal best | <60% predicted/ personal best |
| | Validated Questionnaires | | | |
| | ATAQ | 0 | 1–2 | 3–4 |
| | ACQ | <0.75* | 1, 5 | N/A |
| | ACT | ≥20 | 16–19 | ≤15 |
| Risk | Exacerbations | 0–1/year | | |
| | | Consider severity and interval since last exacerbation | | |
| | Progressive loss of lung function | Evaluation requires long-term follow-up care | | |
| | Treatment-related adverse effects | Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk. | | |

*ACQ values of 0.75–1.4 are indeterminate regarding well-controlled asthma.

Key: EIB, exercise-induced bronchospasm; FEV₁, forced expiratory volume in 1 second. See figure 3–8 for full name and source of ATAQ, ACQ, ACT.

National Heart, Lung and Blood Institute; National Asthma Education and Prevention Program; Expert Panel Report 3: Guidelines for Diagnosis and Management of Asthma, Full Report 2007.

Monitoring Control in Clinical Practice: Asthma Control Test™ for Patients Aged ≥12 Years¹

- In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, school or at home?
 All of the time Most of the time Some of the time A little of the time None of the time
- During the past 4 weeks, how often have you had shortness of breath?
 More than once a day Once a day 3 to 6 times a week Once or twice a week Not at all
- During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain) wake you up at night or earlier than usual in the morning?
 4 or more nights a week 2 or 3 nights a week Once a week Once or twice Not at all
- During the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication (such as albuterol)?
 3 or more times per day 1 or 2 times per day 2 or 3 times per week Once a week or less Not at all
- How would you rate your asthma control during the past 4 weeks?
 Not controlled at all Poorly controlled Somewhat controlled Well controlled Completely controlled

Level of Control Based on Composite Score²

≥20 = Controlled

16-19 = Not Well Controlled

≤15 = Very Poorly Controlled

Regardless of patient's self assessment of control in Question 5

1. Asthma Control Test™ copyright, QualityMetric Incorporated 2002, 2004. All rights reserved.
 2. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthma_tqr_resource.pdf. Accessed February 5, 2007.

49

Classifying Asthma Control: Youths Aged ≥12 Years and Adults

| Components of Control | Well Controlled | Not Well Controlled | Very Poorly Controlled |
|---|--|--|--|
| Symptoms | ≤2 days/week | >2 days/week | Throughout the day |
| Nighttime awakening | ≤2 times/month | 1 to 3 times/week | ≥4 times/week |
| Interference with normal activity | None | Some limitation | Extremely limited |
| SABA use for symptom control (not prevention of EIB) | ≤2 days/week | >2 days/week | Several times per day |
| FEV ₁ or peak flow | >80% predicted/ ^a personal best | 60% to 80% predicted/ ^a personal best | <60% predicted/ ^a personal best |
| Validated questionnaires Asthma Therapy Assessment Questionnaire Asthma Control Questionnaire Asthma Control Test™ | 0 ≤0.75 ^b ≥20 | 1 to 2 ≥1.5 16 to 19 | 3 to 4 NA ≥15 |
| Exacerbations requiring oral systemic corticosteroids | 0 to 1/year | | |
| Progressive loss of lung function | Consider severity and interval since last exacerbitation | | |
| Treatment-related adverse effects | Evaluation requires long-term follow-up care Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk. | | |
| Risk | 0 to 1/year | ≥2/year | |

^aValues of 0.75 to 1.4 are indeterminate regarding well-controlled asthma.
^bAsthma Control Test is a trademark of QualityMetric Incorporated.
 Adapted from the NHL guidelines.
 National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program.
 www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed September 10, 2010.

50

Short Acting Inhaled Beta 2 Agonists

- Albuterol (Proventil HFA, Ventolin HFA, Pro-Air HFA)
 - 2 puffs q 4-6 hours or 2 puffs 15 minutes before exercise
 - Onset: 5 minutes

51

Short Acting Beta-2 Agonist

- Levalbuterol (Xopenex HFA)
 - 1 – 2 inhalations every 4 – 6 hours prn

52

Short-Acting Beta-2 Agonists

- Usage of these medications more than 2 times/week is indicative of poor control
- Regular, scheduled use of these medications is usually not recommended

53

Long-Acting Controller Medications

54

Maintenance or Prevention is the Key

- Good management is the key to preventing exacerbations and hospitalizations
- As with any disease, preventing the problem is always better than treating it

55

Corticosteroids

- Most potent and effective anti-inflammatory medication currently available

56

Inhaled Corticosteroids

- Examples
 - Beclomethasone (Beclivent, Vanceril)
 - Budesonide (Pulmicort turbuhaler)
 - Flunisolide (Aerobid)** No longer produced
 - Fluticasone (Flovent)
 - Triamcinolone Acetonide (Azmacort)*** No longer produced
 - Mometasone (Asmanex)

57

Inhaled Corticosteroids

- Side effects
 - Pharyngitis
 - Dysphonia
 - Oral Candidiasis
- Precautions
 - High dosages: Increased systemic absorption leading to HPA axis suppression
 - Not indicated for an acute exacerbation

58

To Reduce Side Effects of Inhaled Corticosteroids

- Administer with spacers or holding chambers
- Rinse mouth after inhalation
- Use lowest possible dose to maintain control
- Children - monitor growth

59

Schenkel, E. et. al

- 98 patients randomized to either placebo or mometasone furoate aqueous nasal spray
- Ages: 3 - 9 years
- After 1 year, there was no suppression of height in the children using the nasal corticosteroid when compared with the child using placebo

Pediatrics Vol 105 No. 2 February 2000, p. 22

60

Remember...

- Poorly controlled asthma often delays growth
- In general, children with asthma tend to have longer periods of reduced growth rates prior to puberty

61

Mast Cell Stabilizers

- Cromolyn Sodium (Intal)
- No longer being manufactured - if not already unavailable, soon to be

62

Mast Cell Stabilizers

- Mechanism of Action
 - Reduces the production of histamine and prevents the release from the mast cell
- MDI or Nebulizer Solution
 - MDI: ≥ 5 years: 2 puffs po qid
 - Nebulizer Solution: ≥ 2 years: 1 ampule qid
 - Begin to work within 15 minutes of inhalation but can take up to 2 weeks to become effective

63

Mast Cell Stabilizer

- Side effects
 - Generally well tolerated
 - Side effects occur in 1:10,000
 - Cough
 - Wheezing
 - Rash
 - Nausea
- Category B

64

Leukotriene Receptor Antagonists

- Cysteinyl leukotriene production in the body has been associated with airway edema, smooth muscle constriction and the inflammatory process
- These medications block the leukotriene receptors which in turn is able to prevent inflammation and bronchoconstriction

65

Leukotriene Receptor Antagonists

- (Zafirlukast) Accolate
 - 10mg bid for ages 5-11
 - 20mg bid for 12 and older
 - Studied in children as young as 5
 - Avoid food 1 hour before and 2 hours after taking: Food decreases the bioavailability of Accolate
 - Metabolism: Metabolized through the CY P450 2C9 and 3A4 pathways
 - Major pathways in the body
 - Numerous other medications use this same pathway

66

Zafirlukast (Accolate)

- Drug/Drug Interactions
 - Aspirin: Increased zafirlukast levels by 40%
 - Erythromycin: 40% decrease in zafirlukast
 - Theophylline: Postmarketing reports of increased theophylline levels
 - Coumadin: 35% increase in PT/INR

67

Zafirlukast (Accolate)

- Side effects
 - Headache (12.9%)
 - Dizziness
 - Nausea
 - Churg Strauss syndrome
- Pregnancy: B
- Precautions
 - Not for an acute exacerbation

68

Montelukast (Singulair)

- (Montelukast) Singulair
 - 4 mg Granules once daily: 12 – 23 months
 - 4 mg tablet for children 2 - 5 years of age
 - 5mg qhs for ages 6-14
 - 10mg qhs for ages 15 and older

69

Montelukast (Singulair)

- Drug Interactions
 - Metabolized through CYP2A6 (minor pathway)
 - Phenobarbital: decreases montelukast but no dosage adjustment is required
- Side effects: headache, fatigue, dizziness, Churg-Strauss
- Precautions
 - Not for an acute exacerbation
- Category: B

70

Methylxanthines

- Theophylline
 - Theo-24, Theo-Dur, Uni-Dur, Slo-Bid
 - Bronchodilates and increases the force with which the diaphragm contracts
 - 6 years and older
 - Difficult to manage and as a result has not really gained wide spread acceptance
 - Indicated for individuals with moderate to severe asthma
 - Numerous drug interactions

71

Theophylline

- Numerous medications, foods and chemicals interact with theophylline
 - All of the following decrease theophylline levels
 - Smoking (cigarettes and marijuana)
 - High protein/low carbohydrate diet
 - Phenytoin
 - Phenobarbital
 - Carbamazepine
 - Ketoconazole
 - Diuretics

72

Theophylline

- Theophylline levels (normal 6-15mcg/dL)
 - 15-25: GI upset, N/V, diarrhea, abdominal pain
 - 25-35: Tachycardia, occasional PVC's
 - >35: Ventricular tachycardia, seizures
- Category: C

73

Long Acting Inhaled Beta 2 Agonist

- Salmeterol (Serevent)
 - Diskus
 - ≥ 4 years of age-1 puff po q 12 hours
 - No role for acute exacerbations
 - Seems to help children affected by the nocturnal cough and wheezing
 - Good for prevention of exercise induced asthma

74

Long Acting Inhaled Beta 2 Agonist

- Foradil Aerolizer
 - ≥ 5 years of age: 1 inhalation every 12 hours
 - Also may be used for prevention of EIB

75

Combination Products

- Mometasone/formoterol
 - Dulera
- Fluticasone/salmeterol
 - Advair
- Budesonide/formoterol
 - Symbicort

76

LABA

- FDA warning regarding increased deaths in patients treated with LABA
 - Should be used only with inhaled corticosteroid
 - Should be used for shortest length of time to control symptoms

www.fda.gov/CDER/Drug/infopage/LABA/default.htm accessed 07-20-2010

Wright, 2011

Omalizumab (Xolair)

- Indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or *in vitro* reactivity to a perennial aeroallergen
- And...whose symptoms are inadequately controlled with inhaled corticosteroids
- SC injection

78

Omalizumab (Xolair)


- Recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human immunoglobulin E (IgE).
- Inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils
- Limits the degree of release of mediators of the allergic response.

79

Last....


- Don't forget to treat the nose
- 85% of individuals with asthma have concomitant allergic rhinitis

80



Wright, 2011

81




Wright, 2011

82






Wright, 2011

83



Wright, 2011

84



Acute Asthma Exacerbation Management

88

- ### Acute Asthma Exacerbation
- Measure FEV1
 - Inhaled short acting beta 2 agonist: Up to three treatments of 2-4 puffs by MDI at 20 minute intervals OR a single nebulizer
 - Can repeat x 1 – 2 provided patient tolerates
 - Prednisone
 - What dose and schedule??
- 89

- ### Management of Moderate Exacerbations: Response from ED Treatment
- Good Response
 - Symptom relief sustained x 1hr; FEV1 or PEF \geq 70%
 - D/C home
 - Continue SABA & oral corticosteroid
 - Consider inhaled corticosteroid (ICS)
 - Patient education / asthma action plan
- 90 90

Management of Moderate Exacerbations:
Response from ED Treatment

- Incomplete Response
 - Mild-moderate symptoms, FEV1 or PEF 40-69%
 - SABA, oxygen, oral or IV corticosteroids
 - Can D/C home
- Poor Response
 - Marked symptoms, PEF <40%
 - Repeat SABA immediately
 - ED / 911; oral corticosteroid

91 91

Key Differences in the EPR-3 Report

- Point of discharge
 - FEV1 or PEF \geq 70% predicted
 - Response sustained 60 minutes after last treatment
 - Normal physical exam
- Continued ED treatment needed
 - FEV1 or PEF 40-69% predicted
- Consider adjunct therapies
 - FEV1 or PEF <40% predicted

92 92

Thank you for your time and attention.

Wendy L. Wright, MS, APRN, BC, FAANP
WendyARNP@aol.com

93